MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials

被引：48

作者：

Koutcher, JA

Hu, XY

Xu, S

Gade, TPF

Leeds, N

Zhou, XHJ

Zagzag, D

Holland, EC

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Radiol, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Cell Biol, New York, NY 10021 USA

[5] MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA

[6] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA

[7] NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA

[8] Mem Sloan Kettering Canc Ctr, Dept Surg Neurosurg, New York, NY 10021 USA

[9] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA

来源：

NEOPLASIA | 2002年 / 4卷 / 06期

关键词：

MRI; brain tumor; screening; glioblastoma; oligodendrogliomas;

D O I：

10.1038/sj.neo.7900269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Magnetic resonance imaging (MRI) has been utilized for screening and detecting brain tumors in mice based upon their imaging characteristics appearance and their pattern of enhancement. Imaging of these tumors reveals many similarities to those observed in humans with identical pathology. Specifically, high-grade murine gliomas have histologic characteristics of glioblastoma multiforme (GBM) with contrast enhancement after intravenous administration of gadolinium diethylenetriamine pentaacetic acid (Gd-DTPA), implying disruption of the blood-brain barrier in these tumors. In contrast, low-grade murine oligodendrogliomas do not reveal contrast enhancement, similar to human tumors. MRI can be used to identify mice with brain neoplasms as inclusion criteria in preclinical trials.

引用

页码：480 / 485

页数：6

共 31 条

[1] Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts [J].

Bhujwalla, ZM ;

Artemov, D ;

Natarajan, K ;

Ackerstaff, E ;

Solaiyappan, M .

NEOPLASIA, 2001, 3 (02) :143-153

[2]

BLANKENBERG F, 1991, AM J NEURORADIOL, V12, P543

[3]

Chenevert TL, 1997, CLIN CANCER RES, V3, P1457

[4] Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors [J].

Chenevert, TL ;

Stegman, LD ;

Taylor, JMG ;

Robertson, PL ;

Greenberg, HS ;

Rehemtulla, A ;

Ross, BD .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (24) :2029-2036

[5] Use of reporter genes for optical measurements of neoplastic disease in vivo [J].

Contag, CH ;

Jenkins, D ;

Contag, FR ;

Negrin, RS .

NEOPLASIA, 2000, 2 (1-2) :41-52

[6] PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo [J].

Dai, C ;

Celestino, JC ;

Okada, Y ;

Louis, DN ;

Fuller, GN ;

Holland, EC .

GENES & DEVELOPMENT, 2001, 15 (15) :1913-1925

[7]

Edinger Matthias, 1999, Neoplasia (New York), V1, P303, DOI 10.1038/sj.neo.7900048

[8] Applications of magnetic resonance in model systems: Cancer therapeutics [J].

Evelhoch, JL ;

Gillies, RJ ;

Karczmar, GS ;

Koutcher, JA ;

Maxwell, RJ ;

Nalcioglu, O ;

Raghunand, N ;

Ronen, SM ;

Ross, BD ;

Swartz, HM .

NEOPLASIA, 2000, 2 (1-2) :152-165

[9] Development of a flexible and specific gene delivery system for production of murine tumor models [J].

Fisher, GH ;

Orsulic, S ;

Holland, E ;

Hively, WP ;

Li, Y ;

Lewis, BC ;

Williams, BO ;

Varmus, HE .

ONCOGENE, 1999, 18 (38) :5253-5260

[10] Magnetic labeling of activated microglia in experimental gliomas [J].

Fleige, G ;

Nolte, C ;

Synowitz, M ;

Seeberger, F ;

Kettenmann, H ;

Zimmer, C .

NEOPLASIA, 2001, 3 (06) :489-499

← 1 2 3 4 →